These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36916168)

  • 41. Hyperlipidemia and Nonalcoholic Steatohepatitis Predispose to Hepatocellular Carcinoma Development Without Cirrhosis.
    Phan J; Ng V; Sheinbaum A; French S; Choi G; El Kabany M; Durazo F; Saab S; Tong M; Busuttil R; Han SH
    J Clin Gastroenterol; 2019 Apr; 53(4):309-313. PubMed ID: 29912756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Problem of Growing Magnitude.
    Pocha C; Kolly P; Dufour JF
    Semin Liver Dis; 2015 Aug; 35(3):304-17. PubMed ID: 26378646
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hepatocellular carcinoma and non-alcoholic fatty liver disease.
    Golabi P; Rhea L; Henry L; Younossi ZM
    Hepatol Int; 2019 Nov; 13(6):688-694. PubMed ID: 31701393
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association of nonalcoholic fatty liver disease and liver cancer.
    Schulz PO; Ferreira FG; Nascimento Mde F; Vieira A; Ribeiro MA; David AI; Szutan LA
    World J Gastroenterol; 2015 Jan; 21(3):913-8. PubMed ID: 25624725
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan.
    Akuta N; Kawamura Y; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
    BMC Gastroenterol; 2018 Nov; 18(1):165. PubMed ID: 30400829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Letter to the Editor: Consider More Factors When Studying Risk of Cirrhosis and Hepatocellular Cancer in Patients With Nonalcoholic Fatty Liver Disease.
    Yang NB; Li GX; Chu JG; Wang YJ
    Hepatology; 2020 Jun; 71(6):2172-2173. PubMed ID: 31849080
    [No Abstract]   [Full Text] [Related]  

  • 47. Risk factors and diagnostic biomarkers for nonalcoholic fatty liver disease-associated hepatocellular carcinoma: Current evidence and future perspectives.
    Ueno M; Takeda H; Takai A; Seno H
    World J Gastroenterol; 2022 Jul; 28(27):3410-3421. PubMed ID: 36158261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of metabolic traits with occurrence of nonalcoholic fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis of longitudinal cohort studies.
    Chen J; Song S; Li X; Bian D; Wu X
    Saudi J Gastroenterol; 2022; 28(2):92-100. PubMed ID: 34810377
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
    Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
    Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Hepatocellular carcinoma].
    Czauderna C; Marquardt JU; Galle PR; Wörns MA
    Internist (Berl); 2017 May; 58(5):469-479. PubMed ID: 28386626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
    Zhu C; Zhou D; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NAFLD: Is There Anything New under the Sun?
    Lonardo A; Targher G
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28895919
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Changing Global Epidemiology of Hepatocellular Carcinoma.
    Caines A; Selim R; Salgia R
    Clin Liver Dis; 2020 Nov; 24(4):535-547. PubMed ID: 33012444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.
    Azuma S; Asahina Y; Kakinuma S; Azuma K; Miyoshi M; Inoue E; Tsunoda T; Sato A; Kaneko S; Nagata H; Kawai-Kitahata F; Murakawa M; Nitta S; Itsui Y; Tomita M; Nakagawa M; Watanabe M
    Dig Dis; 2019; 37(3):247-254. PubMed ID: 30625487
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area.
    Yoon CH; Jin YJ; Lee JW
    Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1090-1096. PubMed ID: 29847489
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NAFLD as a risk factor for HCC: new rules of engagement?
    Masuzaki R; Karp SJ; Omata M
    Hepatol Int; 2016 Jul; 10(4):533-4. PubMed ID: 27146835
    [No Abstract]   [Full Text] [Related]  

  • 60. Development and prognosis of hepatocellular carcinoma in patients with diabetes.
    Nakatsuka T; Tateishi R
    Clin Mol Hepatol; 2023 Jan; 29(1):51-64. PubMed ID: 35903020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.